drugset
drugset / Trial / NCT06454266

First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen)

NCT06454266 ↗

Phase 2 Completed 22 enrolled Ningbo No. 1 Hospital
NaSingle-groupOpen-labelTreatment

Summary

Exploring the efficacy and safety of first-line treatment of primary central nervous system lymphoma with the combination of orelabrutinib, rituximab and methotrexate (ORM regimen).

Timeline

Start
2021-12-28
Primary completion
2024-06-30
Completion
2024-07-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Methotrexate Small molecule 3 g —
Subject Orelabrutinib Small molecule 150 mg —
Subject Rituximab Monoclonal antibody 375 mg/m2 —

Indications

primary central nervous system lymphoma